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ABSTRACT: The production of cells capable of carrying multiple
transgenes to Mb-size genomic loci has multiple applications in
biomedicine and biotechnology. In order to achieve this goal, three
key steps are required: (i) cloning of large genomic segments; (ii)
insertion of multiple DNA blocks at a precise location and (iii) the
capability to eliminate the assembled region from cells. In this
study, we designed the iterative integration system (IIS) that
utilizes recombinases Cre, ΦC31 and ΦBT1, and combined it with
a human artiﬁcial chromosome (HAC) possessing a regulated
kinetochore (alphoidtetO-HAC). We have demonstrated that the
IIS-alphoidtetO-HAC system is a valuable genetic tool by
reassembling a functional gene from multiple segments on the HAC. IIS-alphoidtetO-HAC has several notable advantages over
other artiﬁcial chromosome-based systems. This includes the potential to assemble an unlimited number of genomic DNA
segments; a DNA assembly process that leaves only a small insertion (<60 bp) scar between adjacent DNA, allowing genes
reassembled from segments to be spliced correctly; a marker exchange system that also changes cell color, and counter-selection
markers at each DNA insertion step, simplifying selection of correct clones; and presence of an error prooﬁng mechanism to
remove cells with misincorporated DNA segments, which improves the integrity of assembly. In addition, the IIS-alphoidtetO-
HAC carrying a locus of interest is removable, oﬀering the unique possibility to revert the cell line to its pretransformed state and
compare the phenotypes of human cells with and without a functional copy of a gene(s). Thus, IIS-alphoidtetO-HAC allows
investigation of complex biomedical pathways, gene(s) regulation, and has the potential to engineer synthetic chromosomes with
a predetermined set of genes.
KEYWORDS: human artiﬁcial chromosome, HAC, iterative integration system, IIS, DNA assembly, synthetic biology
Since their development, HACs or human artiﬁcialchromosomes have been considered to be a promising
system for gene delivery and expression, with the potential to
overcome many problems caused by the use of virus-based gene
transfer systems. Indeed, HACs are stably maintained as single
copy episomes. Their use avoids the limited cloning capacity,
the lack of copy number control and potential insertional
mutagenesis due to integration into host chromosomes that has
hampered the use of viral vectors.1−7 There are two types of
HACs in general use: “top down” HACs constructed by
truncation of the natural chromosomes and “bottom up” HACs
generated from BACs carrying 30−200 kb DNA from natural
higher-order centromeric DNA repeats. Such BACs are
substrates for HAC formation in a process that is accompanied
by 20−30-fold multimerization of the input BAC DNA in
human cells. Over the past 20 years, many groups have
reported the successful generation of HACs of both types1−7
(and references therein), and importantly all HACs constructed
so far have constitutive kinetochores.8,9 In the past few years,
the amount of research based on the HAC-vectors has
signiﬁcantly increased due to the engineering of HACs with a
single loxP gene integration site3,10,11 (and references therein).
Such research has included studies on the potential of HACs
for gene function analysis, cell reprogramming and animal
transgenesis.1−7,12−22
Our group constructed the alphoidtetO-HAC23 from a
synthetic alpha-satellite (alphoid) DNA array with precisely
deﬁned DNA sequence starting from a 343 bp dimer ampliﬁed
by the RCA-TAR method24 up to 50 kb in size. This HAC
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includes approximately 6000 copies of the 42 bp tetracycline
operator (tetO) sequence incorporated into each alphoid
dimer.25 Because the tetO sequence is bound with high aﬃnity
and speciﬁcity by the Tet repressor (TetR), the 1.1 Mb-size
alphoid array in this HAC can be targeted eﬃciently with TetR
fusion proteins that allow the speciﬁc manipulation of
chromatin within the functional kinetochore. This provides a
highly versatile model system for the study of centrochromatin
and its impact on kinetochore structure and function in human
cells.8,9 In addition, this feature of alphoidtetO-HAC gives the
unique possibility to eliminate the HAC from cells, allowing
workers to compare the phenotypes of human cells with and
without a functional copy of a target gene inserted into the
HAC.12,13 Such rigorous control is important for proper
interpretation of gene complementation analysis and studies of
new gene function. Recently the alphoidtetO-HAC was applied
to investigate the problem of chromosome instability (CIN),
involving the unequal distribution of chromosomes to daughter
cells during mitosis which is observed in the majority of solid
tumors. While CIN acts as a driver of cancer genome evolution
and tumor progression, recent ﬁndings point to the existence of
a threshold level beyond which CIN becomes a barrier to
tumor growth and, therefore, can be exploited therapeuti-
cally.26,27 Newly developed alphoidtetO-HAC-based assays allow
for a quick and eﬃcient screening of hundreds of drugs to
identify those aﬀecting chromosome mis-segregation and also
to rank compounds with the same or similar mechanism of
action based on their eﬀect on the rate of chromosome
loss.28−30 The fact that the HAC is nonessential in the absence
of Blasticidin selection greatly simpliﬁes the interpretation of
these assays. Similarly, the alphoidtetO-HAC-based approach
was used to identify new human CIN genes,31 mutations in
which are thought to be an early event in tumor development
predisposing cells to the accumulation of genetic changes
leading to progression to a cancerous state.
A few years ago several laboratories suggested using artiﬁcial
chromosomes (AC) to assemble entire genomic loci using a
multi-integrase system.32−36 Such an AC-based approach opens
new horizons for synthetic biology, especially in higher
eukaryotes. In this study, we designed an iterative integration
system (IIS) in such a way that potentially renders it capable of
accepting an unlimited number of DNA fragments. In general,
IIS is a method to construct large segments of transgenic DNA
in a vertebrate host genome. Our IIS method is based on three
recombinase enzymes, i.e., Cre, ΦC31 and ΦBT1. Cre is a
bidirectional enzyme that catalyzes the recombination between
two substrate loxP sites and generates two product loxP sites. In
contrast, in the absence of an additional protein Xis,
recombinases ΦC31 and ΦBT1 are unidirectional enzymes
that recombine an attachment bacteria (attB) site and an
attachment phage (attP) site to produce attR and attL sites that
are not substrates for further reaction. A novel IIS system was
combined with alphoidtetO-HAC.
The IIS-alphoidtetO-HAC system can be used to assemble and
deliver large DNA fragments that include groups of genes for
functional studies. In future, a new HAC-based multi-integrase
system carrying multiple genes may be a unique tool for
treatment of multigene genetic disorders and for transgenesis
experiments with the purpose to understand complex diseases.
In addition, the IIS-alphoidtetO-HAC system provides a
potentially valuable genetic tool to engineer synthetic
chromosomes with a predetermined set of genes in order to
investigate complex biomedical pathways and gene(s) regu-
lation.
■ RESULTS
Construction of Plasmids for the IIS-alphoidtetO-HAC
System. Five basic plasmids were constructed for the IIS-
alphoidtetO-HAC system: the platform cassette A037 on which
DNA fragments/genes can be assembled, two carrier vectors
used to deliver the transgenic DNA fragments containing
promoterless compound markers called either PCF (Pac-
mCherry-FcYFur) (Type I A167 plasmid) or GHT (eGFP-
hph-TK) (Type II A169 plasmid) and two recombinase
expression plasmids that express either Cre and ΦBT1
(A135-JH) or Cre and ΦC31 (A139) (Figure 1) (for
construction details, see Methods and Figures S1−S5).
The platform cassette A037 consists of the SFM promoter
(SV40 enhancer plus Feritin promoter), a split mouse
elongation factor 1 (mEF1) intron containing a loxP site
within, the GHT marker and the attB site of ΦC31 (Figure 1a).
The platform cassette was targeted into the unique human
Ch13 genomic segment present within alphoidtetO-HAC12 using
homologous recombination in a highly recombinogenic chicken
B-lymphoma DT40 cells (Figure 2a). Before targeting, the
platform cassette was XhoI-linearized to release 5′ M2A and 3′
M2B hook sequences of 3.5 kb and 3.9 kb in size, respectively,
which have homology to the Chr13 genomic segment (see
Methods for details). Four pairs of diagnostic primers were
used to verify correct insertion of the platform cassette into the
Ch13 segment. The expected size products of 4.4 kb and 3.9 kb
with B128/B124 and B129/B126 pairs of primers, correspond-
ingly, and 4.6 kb and 4.4 kb with the B034/B126 and B034/
B127 pairs of primes, correspondingly, (Table S1) conﬁrms
correct recombination between the M2A and M2B hook
sequences and homologous sequences of the Ch13 segment
(Figure 2b). After insertion of the platform cassette into the
HAC, the cells became green (GFP+), resistant to Hygromycin
and sensitive to Ganciclovir. Next, the alphoidtetO-HAC
carrying the platform cassette was moved from chicken DT40
cells to hamster CHO cells by Microcell-Mediated Chromo-
some Transfer (MMCT) (Figure 2a). A FISH image of the
alphoidtetO-HAC in CHO cells (Clone #CHO BH3:37) is
shown in Figure 2c.
The Type I and Type II carrier vectors, A167 and A169,
correspondingly, were constructed to deliver a transgenic DNA
segment of interest into the platform cassette inserted into the
HAC (Figures 1b, 1c). These carrier vectors are YAC-BAC
shuttle vectors and, therefore, can propagate in a single
molecule state within E. coli as a bacterial artiﬁcial chromosome
(BAC) with chloramphenicol selection and in S. cerevisiae as a
yeast artiﬁcial chromosome (YAC) with the yeast HIS3 gene as
a selectable marker. Insertion of a transgenic DNA segment
into the carrier vector can be done via DNA ligation or yeast-
based transformation-associated recombination (TAR) clon-
ing.37−41 The Type I carrier vector A167 contains in 5′−3′
order a loxP site, a promoterless PCF marker, an attB′′ ΦBT1
site, a cloning site for DNA insertion, an attP ΦC31 site, a
GHT marker under a CAGG promoter ﬂanked by tDNA
insulators42,43 and a YAC-BAC backbone (Figure 1b). The
Type II carrier vector A169 contains a loxP site, a promoterless
GHT marker, an attB ΦC31 site, a cloning site for DNA
insertion, an attP′′ ΦBT1 site, a PCF marker under a CAGG
promoter ﬂanked by tDNA insulators and a YAC-BAC
backbone (Figure 1c). For the purpose of TAR cloning37,44
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short mammalian genomic DNA segments that do not have
yeast ARS-like sequences for a proper propagation in yeast
cells, a variant of each carrier vector was made containing yeast
origin of replication (ARS), i.e., Type I-ARS (A168) and Type
II-ARS (A170) (Figures 1b, 1c and Figures S6, S7).
Two expression plasmids were constructed for the IIS-
alphoidtetO-HAC system. In these plasmids, a P2A self-cleaving
peptide is used to translationally link the expression of two
recombinases so that the two recombinases are expressed in
equal ratio. The plasmid A135-JH expresses Cre recombinase
and ΦBT1 integrase (Figure 1d) while the plasmid A139
expresses Cre recombinase and ΦC31 integrase (Figure 1e).
These plasmids also contain a Zeocin marker that is
transcriptionally linked to the recombinase expression via an
internal ribosomal entry site (IRES), allowing selection of these
plasmids if desired.
Description of the IIS-alphoidtetO-HAC System. The
IIS-alphoidtetO-HAC system works as follows. It starts with
CHO cells containing alphoidtetO-HAC bearing the platform
cassette A037 (Figure 3a). As the GHT marker is expressed, the
cells are green (GFP), Hygromycin resistant (hph) and are
killed upon exposure to Ganciclovir (TK). Next, these cells are
cotransformed with two plasmids, i.e., the A139 plasmid that
expresses Cre recombinase and ΦC31 integrase and the Type I
carrier vector A167 that contains a transgenic DNA segment of
interest (DNA1). Expression of Cre and ΦC31 promotes two
recombination events (loxP−loxP and ΦC31attB-attP) be-
tween the Type I vector and the platform cassette (Figure 3b).
The order of recombination is unimportant as the ﬁnal product
is identical. The SFM promoter within the platform cassette
now drives the promoterless PCF marker and contains the
adjacent attB′′ ΦBT1 site from the Type I vector, as the
original GHT marker is replaced with the PCF marker. This is
accompanied by integration of the DNA segment of interest
(DNA1) into the platform cassette within the HAC and
deletion of all other components of the Type I vector. As a
result, the cells that successfully complete both recombination
reactions lose green ﬂuorescence and sensitivity to Ganciclovir
and gains red ﬂuorescence, resistance to Puromycin and
sensitivity to 5-Fluorocytosine.
An error detection mechanism was built into the IIS-
alphoidtetO-HAC system because the recombinase-mediated
reactions can fail to go to completion. Furthermore, growth,
maintenance, screening and storage of candidate vertebrate
colonies are far slower, more labor intensive and space limited
than either in yeast or bacteria. Thus, it was desirable to remove
as many faulty colonies as possible by drug selection and keep
only the best candidates for subsequent detailed character-
ization.
If either of the two recombination reactions fails, this failure
event can be selected against and screened out by the error
prooﬁng design of the IIS-alphoidtetO-HAC system (Figure 4).
As illustrated, the backbone of each carrier vector has its own
constitutively active compound marker. Hence, if recombina-
tion by Cre fails but ΦC31 occurs (Figure 4a), the A167 Type I
carrier vector will integrate into the platform cassette but the
PCF marker it carries will remain promoterless. Cells carrying
this error are removed by Puromycin selection and counter-
selection with Ganciclovir. Alternatively, if recombination by
ΦC31 fails but Cre occurs (Figure 4b), the Type I vector A167
will integrate into the construction platform and the SFM
promoter will capture the PCF marker, leaving the original
GHT marker promoterless. However, the backbone of the
Figure 1. Scheme of plasmids used in the IIS-alphoidtetO-HAC system.
(a) The platform cassette A037. (b) Type I A167 and Type I-ARS
A168 carrier plasmids to deliver a genomic DNA fragment. (c) Type II
A169 and Type II-ARS A170 carrier plasmids to deliver a genomic
fragment. (d) A135-JH plasmid expressing ΦBT1 integrase and Cre
recombinase. (e) A139 plasmids expressing ΦC31 integrase and Cre
recombinase. Restriction sites used in this work are marked in blue.
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Type I vector is retained, and a fully expressed GHT marker
under the CAGG promoter remains. Hence, cells generated by
such a failure event are Puromycin resistant and have both red
and green ﬂuorescence. These types of cells can be removed by
counter selection using Ganciclovir against the thymidine
kinase component of the GHT marker. In order to avoid the
loss of TK gene activity by silencing, the GHT marker is
protected by ﬂanking murine tDNA insulators.
Once the ﬁrst round of recombination is completed
(DNA1), the second round of DNA integration (DNA2) can
be started. The platform cassette in the HAC now contains a
loxP site, an expressed PCF marker and an attB′′ ΦBT1 site
(Figure 3c). Expression from the PCF marker gives the cells red
ﬂuorescence, resistance to Puromycin and sensitivity to 5-
Fluorocytosine. Next, the cells are cotransformed with plasmid
A135-JH expressing Cre recombinase and ΦBT1 integrase and
the Type II carrier vector A169 containing a second transgenic
DNA segment of interest (DNA2). Cre and ΦBT1 expression
causes two recombination events (loxP−loxP and ΦBT1
attB′′−attP′′) between the Type II vector and the platform
cassette (Figure 3d). This leads to the replacement of the PCF
marker by the GHT marker and an attB′′ ΦBT1 site, followed
by the insertion of the second DNA segment of interest
(DNA2) from the Type1 carrier vector. As a result, the
platform cassette in the HAC will contain a loxP site, an
expressed GHT marker and an attB′′ ΦBT1 site (Figure 3e). A
small insertion (<60 bp) scar comprising the recombination
product of attB/attP, the attR site is left between the ﬁrst
(DNA1) and the second (DNA2) DNA segments of interest.
Selection with Hygromycin and counter selection with 5-
Fluorocytosine ensures that only cells that have correctly
undergone the second round of assembly will survive (Figures
Figure 2. Insertion of the platform cassette into alphoidtetO-HAC in hamster CHO cells. (a) The XhoI-linearized platform cassette A037 was inserted
into the Ch13 genomic segment present within alphoidtetO-HAC by homologous recombination in DT40 cells. Then the alphoidtetO-HAC carrying
the platform cassette was MMCT transferred from chicken DT40 cells to hamster CHO cells. (b) Diagnostic PCRs to verify correct targeting of the
platform cassette A037 into the Ch13 region present within the HAC. Two pairs of diagnostic primes, B128/B124 and B129/B126, ampliﬁed the
expected products of 4.4 kb and 3.9 kb in size, respectively, conﬁrming correct recombination between the M2A hook sequence of A037 and a
homologous sequence of the Ch13 segment. Two pairs of diagnostic primes, B034/B126 and B034/B127, ampliﬁed the expected products of 4.6 kb
and 4.4 kb in size, respectively. This conﬁrmed the correct recombination between the M2B hook sequence of A037 and a homologous sequence of
the Ch13 segment. M, a GeneRuler DNA ladder mix (Fermentas). Lane 1, DT40 cells carrying alphoidtetO-HAC without A037 insertion (a negative
control); Lane 2, targeted DT40:BH3:A037 clone #48; Lane 3, targeted DT40:BH3:A037 clone #49. (c) FISH analysis of the alphoidtetO-HAC
carrying the platform cassette in CHO cells. Arrows indicate to the HAC visualized with the BAC speciﬁc probe (in red).
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4c, 4d). Untransformed parental cells and cells with incomplete
recombination are killed by this double selection.
After two rounds of recombination, the construction
platform is once again where it started, with the exception
that two DNA segments (DNA1 and DNA2) of interest have
now been integrated into the HAC (Figure 3e). The GHT
marker is expressed and the cells have once again green
ﬂuorescence, Hygromycin resistance and sensitivity to
Ganciclovir. Further rounds of DNA fragment insertions can
be repeated indeﬁnitely as required.
Proof of Site-Speciﬁc Recombination Using the IIS-
alphoidtetO-HAC System. First, we tested whether the ΦBT1
and ΦC31 integrases and Cre recombinase were active and
could mediate proper integration into alphoidtetO-HAC carrying
the platform plasmid. For this purpose, control experiments
were performed using empty vectors. The recombinant assay
plasmids were transfected into hamster CHO cells containing
the HAC in the combinations A167 plus A139 or A169 plus
A135-JH. Each step of insertion was conﬁrmed by PCR.
At the beginning of the experiments, hamster CHO cells
carrying the alphoidtetO-HAC bearing the platform cassette
were green (GFP+) (Clone #CHO BH3:37). PCR of genomic
DNA isolated from the initial CHO cells carrying the HAC
gave the expected 778 bp product with the forward primer for
the thymidine kinase (TK) gene (B075) and reverse primer for
the M2B hook sequence (B681) and no product with the
forward primer for the cytidine deaminase gene (FcyFur)
(B485) and the reverse primer for the hook M2B sequence
(B681) (Figures S8a, S8b; Lane 1) (Table S1).
For the ﬁrst round of insertion, CHO cells carrying the
alphoidtetO-HAC bearing the platform cassette were cotrans-
fected by Type I carrier plasmid A167 and plasmid A139
expressing ΦC31 integrase and Cre recombinase. The cells
were cultured in Puromycin/Blasticidin S media. After 10 days
of selection, ﬁve colonies possessing red but not green
ﬂuorescence were picked up and cultured in individual wells
in Puromycin/Ganciclovir/Blasticidin S media. In three
colonies, insertion of the 2.7 kb Ampicillin resistant gene plus
pBR322 DNA fragment from the plasmid A167 into the
platform cassette was conﬁrmed by PCR with a pair of
corresponding primers: forward B485 and reverse B681 (Table
S1). Cells bearing this insertion gave the expected 4.1 kb
product with B485/B681 primers but no product with B075/
Figure 3. Scheme of DNA segment integration by the iterative integration system (IIS). (a) The starting platform cassette. Cells express the GHT
marker, i.e., a green ﬂuorescence protein (GFP). Also, they are hygromycin resistant (hph) and Ganciclovir sensitive (TK). (b) Recombination
between a Type I carrier vector and a platform cassette by Cre recombinase and ΦC31 integrase. The GHT marker is replaced by the PCF marker
and the ﬁrst DNA segment of interest is integrated into the platform cassette (DNA1). The integration event is selected using Puromycin and
Ganciclovir. (c) A structure of the platform cassette after the 1st round of integration. The PCF marker is expressed. Therefore, the cells have red
ﬂuorescence (mCherry), Puromycin resistance (Pac) and 5-Fluorocytosin sensitivity (FcyFur). (d) Recombination between a Type II carrier vector
and a platform cassette by Cre recombinase and ΦBT1 integrase. The PCF marker is replaced by the GHT marker and the second DNA segment of
interest is integrated into the platform cassette (DNA2). The integration event is selected using Hygromycin and 5-Fluorocytosine. (e) A structure
of the platform cassette after the second round of recombination. The cells express the GHT marker, i.e., a green ﬂorescence protein (GFP). They
become again Hygromycin resistant (hph) and Ganciclovir sensitive (TK). This structure is identical to the stating cassette aside from the integration
of DNA segments of interest, DNA1 and DNA2.
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B681 primers (Figures S8a, 8b; Lanes 2). Clone #E10 was
chosen for further experiments.
For the second round of insertion, the cells were
cotransfected by Type II carrier plasmid A169 and A135-JH
plasmid expressing ΦBT1 integrase and Cre recombinase. The
cells were cultured in Hygromycin/Blasticidin S media. After 10
days of selection, ten colonies expressing green but not red
ﬂuorescence were picked up and expanded in media containing
Hygromycin/5-Fluorocytidine/Blasticidin S. For nine colonies,
PCR of genomic DNA isolated from these cells gave the
expected 6.2 kb PCR product with B075/B681 primers but no
product with B485/B681 primers. This conﬁrmed the correct
insertion of the 2.7 kb fragment carried by plasmid A169
(Figures S8a, S8b; Lanes 3). Clone #E10−7 was chosen for
further experiments.
For the third round of insertion, the cells were cotransfected
and selected for as in the ﬁrst round. A total number of ten
clones were selected. PCR of genomic DNA isolated from two
clones, Clone #E10−7−3 and Clone #E10−7−1, with B485/
B681 primers gave the expected 9.6 kb product while there was
no product with B075/B681 primers. This conﬁrmed correct
insertion of the 2.7 kb fragment carried by the A167 plasmid.
(Figures S8a, S8b; Lanes 4 and 5).
These results showed that the recombinases are functional
and that site-speciﬁc insertions into IIS-alphoidtetO-HAC could
be achieved.
VHL Gene Reconstruction Using IIS-alphoidtetO-HAC
System. As a proof of principle, we applied the IIS-alphoidtetO-
HAC system to reconstruct the VHL gene. Brieﬂy, the human
VHL gene is ∼17 kb in size and contains three exons. It is
located on chromosome 3 (positions 10137959−10154492;
GHCH38/hg38). Mutations in the gene are associated with
Von Hippel-Lindau (VHL) syndrome that is a dominantly
inherited hereditary cancer syndrome predisposing to a variety
of malignant and benign tumors of the eye, brain, spinal cord,
kidney, pancreas and adrenal glands.
For the experiments, we used the full-length VHL gene TAR-
isolated previously from the total human genomic DNA as a
∼25 kb YAC/BAC molecule.13 Three fragments containing
exon 1, exon 2 or exon 3 of the VHL gene were PCR-ampliﬁed
from the TAR/YAC/BAC clone using speciﬁc primers (Table
S1). The ﬁrst AscI-NotI fragment of 5990 bp in size (positions
Chr3:10137959−10143949; GRCH38/hg38) containing exon
1 along with the VHL promoter and the third AscI-FseI
fragment of 6323 bp in size (positions Chr3:10148169−
10154492) containing exon 3 were ligated with the Type I
carrier vector A168 (Pac-mCherry-FcyFur) that had been
digested by AscI/NotI or AscI/FseI, correspondingly. The
second AscI-NotI fragment of 4221 bp in size (positions
Chr3:10143949−10148169; GRCH38/hg38) containing exon
2 was ligated with the Type II carrier vector A170 (GFP-hph-
TK) that was digested by AscI/NotI (Figure 5a). Three rounds
of insertion were performed to assemble the full-length VHL
gene using the IIS-alphoidtetO-HAC system.
Round 1. A168 vector containing exon 3 and A139 vector
expressing ΦC31 integrase and Cre recombinase were
cotransfected into hamster CHO cells propagating the
alphoidtetO-HAC bearing the platform cassette A037. Cells
with this HAC are originally green (GFP+). After the ﬁrst
round, the cells switched to red (mCherry+), Puromycin and 5-
Fluorocytidine resistant and carried a modiﬁed alphoidtetO-
HAC bearing the inserted exon 3 (Figure 5b). A total of 14
clones were obtained after positive selection, with 4 remaining
after negative selection: Clone #1, Clone #11, Clone #12 and
Clone #14. Clone #14 was chosen for the second round of
insertion.
Round 2. The A170 vector containing exon 2 and the A135-
JH vector expressing ΦBT1 integrase and Cre recombinase
were cotransfected into Clone #14e CHO cells carrying the
Figure 4. Error prooﬁng design of the IIS-alphoidtetO-HAC. (a,b) Products of incomplete recombination between Type I carrier plasmid with an
active GHT cassette. (c,d) Products of incomplete recombination between Type II carrier plasmid with an active PCF cassette. The selection agents
to remove each misassembled product are listed.
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alphoidtetO-HAC bearing the inserted exon 3. After the second
round, the cells switched back to green (GFP+), Hygromycin
and 5-Fluorocytidine resistant and carried the alphoidtetO-HAC
with inserted exon 3 and exon 2 (Figure 5b). After positive
selection, 20 clones were obtained, of which 2 were left after
negative selection: Clone #14−4 and Clone #14−12. Clone
#14−12 was chosen for the third round of insertion.
Round 3. The A168 vector containing exon 1 and the A139
vector expressing ΦC31 integrase and Cre recombinase were
cotransfected into CHO cells carrying the alphoidtetO-HAC
bearing exons 2 and 3. After the third round, the cells switched
to red again (mCherry+), Puromycin, Gancyclovir and 5-
Fluorocytidine resistant. These cells carry an alphoidtetO-HAC
with all three exons inserted (Figure 5b). After positive
selection, 3 clones were obtained, with 2 remaining after
negative selection: Clone #14−12−2 and Clone #14−12−3.
Insertion after each round was conﬁrmed by PCR (Figure 5c)
Figure 5. VHL gene reconstruction using the IIS-alphoidtetO-HAC system. (a) Construction of Type I A168 and Type II A170 carrier plasmids
containing fragments with exon1 or exon 2 or exon 3 of the VHL gene. Positions of the VHL fragments in the human genome (GRCH38/hg38) are
indicated. (b) Three rounds of insertion of the VHL fragments into alphoidtetO-HAC carrying the platform cassette are shown. Representative images
of changing cell color after each round are shown. (c) Diagnostic PCRs for insertion of the VHL fragments after each round of recombination. Round
1: Lanes 1 to 5, diagnostic PCR for the fragment 3 with the expected size 1.7 kb. Lane 1, Clone #1; Lane 2, Clone #11; Lane 3, Clone #12; Lane 4,
Clone #14; Lane 5, genomic DNA from CHO cells as a negative control. Round 2: Lanes 6−10, diagnostic PCR for junction between fragments 2
and 3. The expected size is 688 bp. The expected size for a negative control is 608 bp. Lane 6, Clone #14−4; Lane 7, Clone #14−12; Lane 8,
alphoidtetO-HAC carrying the full-length human VHL gene in CHO cells; Lane 9, a TAR/BAC clone containing the VHL gene; Lane 10, human
genomic DNA as a positive control. Round 3: Lanes 11−14, diagnostic PCR for junction between fragments 1 and 2. The expected size is 2788 bp.
The expected size for a negative control is 2716 bp. Lane 11, Clone #14−12−3; Lane 12, alphoidtetO-HAC carrying the full-length VHL gene in
CHO cells; Lane 13, a TAR/BAC clone containing the VHL gene; Lane 14, human genomic DNA as a positive control. (d) RT-PCR for mRNA of
VHL. The expected product size is 642 bp. Lane 15, Clone #14−12−3; Lane 16, genomic DNA from CHO cells as a negative control; Lane 17,
human genomic DNA from HeLa cell line as a positive control; Lane 18, human genomic DNA from HT1080 cell line as a positive control.
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with corresponding primers (ﬁrst round R3/B678; second
round F23/R23; third round F12/R12) (Table S1).
Reconstruction of a functional human VHL gene was
conﬁrmed by RT-PCR of the reconstituted RNA transcript
from Clone #14−12−3 (Figure 5d) with the primers VHLstart-
F1/VHLexon-3R (Table S1). The PCR product was sequenced
and found to match the correct human VHL sequence (Figure
S9). Note that in order for this mRNA reassembly to work, the
inserted DNA segments were designed so that the ∼60 bp
recombination sites were located within introns, and were
therefore spliced out of the mature RNA transcript.
■ DISCUSSION
At present, there are many methods to produce transgenic cells
for functional studies of genes. The most common methods
rely on either transfection of BAC DNA carrying a gene of
interest into the host cells or transduction with viruses.
However, these methods lead to random integrations into host
chromosomes. As a result of that, the expression level of genes
varies greatly due to position eﬀects and the number of copies
integrated. In addition, the use of viruses limits the size of a
gene that can be successfully transduced. Another popular
approach is based on integration of a gene into a “hot spot” of a
mammalian genome. In this case, homologous recombination
for targeting gene integration is very speciﬁc due to the usage of
a bacteriophage P1-derived Cre recombinase or ΦC31
integrase. However, the eﬃciency of gene integration remains
low. Furthermore, integration of several genes into the same
“hot spot” is very diﬃcult, if at all possible.
Several years ago ﬁve groups developed a principally new
approach to produce transgenic cells.32−36 Their approach was
to combine the usage of artiﬁcial chromosome-based vectors
with a multi-integrase system. This allowed homogeneous gene
expression without integration of the vector carrying the target
genes into host chromosomes. In addition, artiﬁcial chromo-
somes may be transferred from one cell line to another cell line.
Hence, once a chromosome vector expressing a gene of interest
was built, it could be moved and used in many diﬀerent cell
lines.
In this study, we developed a novel human artiﬁcial
chromosome-based system, the IIS-alphoidtetO-HAC. This
system utilizes two compound markers termed GHT and
PCF. Each compound marker is composed of a positive
selection marker, a counter selection marker and a ﬂuorescence
marker. The GHT marker is composed of sequences encoding
green ﬂuorescence protein (GFP), hygromycin phosphotrans-
ferase (hph) and herpesvirus thymidine kinase (Tk). The PCF
marker is composed of sequences encoding puromycin N-
acetyl-transferase (Pac), red ﬂuorescence protein (mCherry),
and a fusion protein of cytosine deaminase and uracil
phosphoribosyl transferase (FcyFur). These compound
markers can be distinguished visually and can be selected for
or counter-selected against using the appropriate drug. The IIS-
alphoidtetO-HAC system includes three enzymes, Cre, ΦC31
and ΦBT1. Binding sites of these enzymes are arranged in a
manner that allows the IIS-alphoidtetO-HAC to use a promoter
capture and a marker exchange strategy to assemble any desired
number of genomic DNA segments. In this strategy, the
compound marker that is expressed switches each time a new
DNA segment is added to the platform cassette of the HAC.
The compound markers allow positive selection for cells where
a new DNA segment is added to the platform cassette and
counter selection against the cells when this event does not
happen. Eﬃciency and accuracy of the IIS-alphoidtetO-HAC
system has been demonstrated by assembling a functional copy
of the VHL gene from multiple DNA segments.
The reassembly of genes from DNA segments by IIS requires
breakage and rejoining junctions to be made to the target gene.
The optimal placement of these junctions needs to fulﬁll several
requirements. First, the breakage-rejoining junctions must be
placed within introns of the target gene. This is necessary as
spent integration sites (attR) (<60 bp) are left between
adjacent DNA segment (see Figure 3) during the gene
assembly process. Placement within introns, allows these
integration sites to be spliced out from mRNA and so avoid
disruption to the exonic coding sequence.
Second, the placement of breakage-rejoining junctions must
not disrupt the splicing eﬃciency of its host intron. Hence, the
breakage and joining junction should not be near any features
critical to intron function such as the splice donor site,
branchpoint sequence, poly pyrimidine tract and the splice
donor site. The spliced donor is on the 5′ end of the intron and
this is easily avoided by placing the junction no closer than
several hundred bp from it. The branchpoint sequence and poly
pyrimidine tract are typically 20−50 bp upstream from the
splice acceptor site (3′ end of intron). These sequences can be
avoided by placing the breakage-rejoining junction several
hundred bp upstream of the splice acceptor sequence. Splice
site prediction software can be used to identify the branch
sequence (i.e.,http://regulatorygenomics.upf.edu/Software/
SVM_BP/ or http://www.umd.be/HSF3/).
Third, insertion of the integrase sites at the breakage-
rejoining junctions should not generate a cryptic splice donor
or acceptor site. Splice prediction software such as http://www.
umd.be/HSF3/ can help predict the creation of cryptic splice
site.
Fourthly, it is envisioned that TAR cloning would be the
preferred method used to clone the gene segments. Hence, the
breakage-rejoining junctions must avoid repeat sequences.
Repeat sequences can be identiﬁed using the “Repeat mask”
option in UCSC DNA download window.
Although several laboratories made a signiﬁcant progress for
synthetic biology by constructing multi-integrase systems on
diﬀerent HACs and MACs, a new IIS-alphoidtetO-HAC system
has some notable advantages that set it apart from other similar
artiﬁcial chromosome-based systems32−36 (Figure S10). First,
the maximum number of DNA segments that can be added to
the IIS-alphoidtetO-HAC is only limited by carrying capacity of a
human chromosome, which is several hundred Mbs. In eﬀect
the IIS-alphoidtetO-HAC can insert any desired number of
genomic DNA segments into the construction platform located
within the HAC. Second, each step of insertion is accompanied
by a change in cell color that simpliﬁes the selection of correct
clones. Third, in this system the insertion “scar” between
adjacent DNA segments is greatly reduced (<60 bp), consisting
of a single recombined integration sites (attR) that could, as
shown here, be incorporated within introns to allow reassembly
a gene from multiple parts. Fourthly, IIS-alphoidtetO-HAC has
an error prooﬁng mechanism to remove mis-incorporated DNA
segments and improve the integrity of assembly. Lastly, as we
have previously shown12,13 alphoidtetO-HAC carrying a gene(s)
of interest can be removed from the cells in culture by targeting
with TetR fusion proteins that allow a unique possibility to
compare the phenotypes of human cells with and without a
functional copy of a gene(s) inserted into the HAC.
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For comparison, previously developed artiﬁcial chromosome-
based systems32,33 are limited to the number of eﬃcient
recombinases known to work in mammalian cells (see Figure
S10a). As a result, the maximum number of fragments that may
be inserted into an artiﬁcial chromosome is low (ﬁve for the
systems published and would be approximately 10 if the
systems were modiﬁed to use all recombinases known to work
in mammalian cells). In response, more advanced systems were
recently developed by the same group that could perform
unlimited multiple insertions34 (see Figures S10c and S10d).
However, all these systems mentioned above retain and
integrate the entire plasmid backbone between DNA segments
inserted into an artiﬁcial chromosome.32−34 Therefore, they
may experience problems assembling functional genes from
gene segments due to the presence of cryptic splice sites or
abnormal pausing of the splicing machinery that may change
splice isoform generation. Similar problems exist in another
artiﬁcial chromosome-based system35 (see Figure S10b).
Moreover, as this system uses multiple (<50) identical platform
cassettes integrated in the chromosome-vector, the relative
position of each new insert relative to one another is
uncontrolled. The maximum number of insertions that can
be added is limited by the number of platform cassettes, and is
further reduced because each round adds an additional loxP site
that may recombine and lead to destabilization of the
chromosome upon Cre exposure. Another system is based on
the principles similar to our system36 (Figure S10e). However,
it has several signiﬁcant distinctions: it does not include color
markers that help to distinguish one round of insertion from
another; it does not have an error prooﬁng mechanism; the
HAC cannot be speciﬁcally and eﬃciently removed from the
host cell cultures.
In summary, the IIS-alphoidtetO-HAC system is able to
eﬃciently and precisely carry out recombination in mammalian
cells that allows the investigator to potentially insert any desired
number of genomic fragments, leading to assembly of a
functional copy of a gene and even more complex loci. The IIS-
alphoidtetO-HAC is a valuable unique genetic tool for
investigating gene(s) function, complex biochemical pathways
and has a great potential for animal transgenesis, development
of therapeutic applications for complex diseases, and synthetic
biology.
■ METHODS
Cell Lines and Culture. Chicken B-lymphoma DT40 cells
containing the alphoidtetO-HAC were cultured in Roswell Park
Memorial Institute medium 1640 (RPMI-1640, GIBCO)
supplemented with 10% fetal bovine serum (Biowest, Nuaille,
France), 1% chicken serum (Invitrogen), 50 μM 2-mercaptoe-
thanol (SIGMA) and 15 μg/mL Blasticidin S (Funakoshi,
Tokyo, Japan) at 40 °C in 10% CO2. Hypoxanthine
phosphoribosyltransferase (HPRT)-deﬁcient Chinese hamster
ovary (CHO) cells (JCRB0218) carrying the alphoidtetO-HAC
were maintained in Ham’s F-12 nutrient mixture (Invitrogen,
USA) plus 10% fetal bovine serum (FBS) with 8 μg/mL
Blasticidin S Hydrochloride (Funakoshi, Japan). Blasticidin S is
required for stable propagation of alphoidtetO-HAC in the
medium.
Construction of Plasmids for the IIS-alphoidtetO-HAC
System. A037: The platform cassette plasmid was constructed
in two parts. The promoter and GHT marker components were
ampliﬁed from multiple plasmid sources while the recombinase
recognition sites, loxP and attB, ΦC31 were added by PCR
using long oligomers. The GHT compound marker is
composed of a fusion of Green Fluorescence Protein (GFP),
P2A self-cleaving peptide, Hygromycin phosphotransferase
(hph) and viral Thymidine Kinase (TK). The Chr13 targeting
hooks (M2A and M2B) were PCR ampliﬁed from human
genomic DNA and added to the construct. The construction
steps and primer sequences used are depicted in Figure S1 and
Table S1, respectively.
A167, A168, A169 and A170: The carrier plasmids were
constructed in three sections: (i) the integration cassette that
comprises of a promoterless compound marker with appro-
priate recombinase recognition sites; (ii) the error prooﬁng
cassette, which is composed of an expressed compound marker
opposite to promoterless marker; (iii) the YAC-BAC shuttle
vector. Two compound markers were built, the GHT and PCF
markers. The GHT marker is as previously described while the
PCF marker is a fusion of Puromycin N-acetyl-transferase
(Pac), 2A self-cleaving peptide, mCherry ﬂuorescence protein, a
second 2A self-cleaving peptide, and cytosine deaminase fused
to uracil phosphoribosyl transferase (FcyFur). The construction
steps of the Type I carrier plasmid without ARS (A167) and
with ARS (A168) are shown in Figure S2 and Figure S6,
respectively. The construction steps of the Type II carrier
plasmids without ARS (A169) and with ARS (A170) are shown
in Figure S3 and Figure S7, respectively. All construction
primers used are listed in Table S1
A135-JH and A139: These are the vectors that express
recombinases ΦBT1 and Cre, ΦC31 and Cre, respectively.
Each vector expresses two recombinases as a single peptide,
linked by a 2A-self-cleaving peptide. The construction steps of
A135-JH and A139 are shown in Figure S4 and Figure S5,
respectively. All construction primers used are listed in Table
S1.
Insertion of the Platform Cassette A037 into the
AlphoidtetO-HAC in Chicken DT40 Cells. The platform
cassette A037 was targeted into the human Ch13 segment
present within alphoidtetO-HAC using homologous recombina-
tion in a highly recombinogenic chicken B-lymphoma DT40
cell line. Before targeting, the platform cassette was digested
and linearized by XhoI to release M2A (positions
Ch13:69420033−69523541; GRCH38/hg38) and M2B (posi-
tions Ch13:69523556−69527457; GRCH38/hg38) hook
sequences that have homology to the Ch13 segment. 90 clones
were obtained under Hygromycin selection. PCR analysis of
genomic DNA from these clones using speciﬁc primers (Table
S1) conﬁrmed insertion of the platform cassette into the HAC
in 14 of the clones.
One Platform Cassette Per AlphoidtetO-HAC, Per Cell.
In order for the IIS-HAC system to stably work, only one
platform cassette can be present within the HAC and only one
cassette within the cell in total. Consequently several strategies
and assays were conducted to ensure there was only one
platform cassette within the HAC and cell. First, the platform
cassette was inserted into a positon within the HAC that was
previously found to be unique, using homologous recombina-
tion in chicken DT40 cell. Targeting was conﬁrmed by PCRs.
Hence, there should only be one copy of the platform cassette
in the HAC. Second, the HAC containing the platform cassette
was then transferred from chicken DT40 to hamster CHO cells
by MMCT, thereby removing any copies of the platform
cassette that may have integrated into the genome of the DT40
cell. Third, we also conducted ﬂuorescence in situ hybridization
(FISH) in conjunction with colony subcloning to ensure that
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the CHO cells we worked with had only a single HAC and thus
one copy of the platform cassette. Fourthly, the double
selection system of IIS innately selects against the presents of
more than one platform cassette. Hamster CHO cells, like
many cancer cell line, experience chromosome instability.
Hence the copy number of the HAC has been observed to
spontaneously increase in a small percentage of cells during
culturing. This issue is addressed in the IIS-HAC-based system
by its compound markers that allow both positive selection and
negative counter-selection which are conducted at each round
of integration. More speciﬁcally, if there were two platform
cassettes expressing the GHT marker (GFP-hph-TK) in the
HAC, the integration of a DNA fragment with a promoterless
PCF (Pac-mCherry-FcyFur) marker into one cassette would
result in a cell expressing the PCF marker from one cassette
and the GHT marker from the second cassette. The double
selection with both puromycin (positive selection for Pac) and
ganciclovir (counter-selection against TK) would remove such
cells with one or more platform cassettes. Only cells with one
platform cassette with the right compound marker can survive
rounds of positive selection and negative counter-selection.
Lastly and more importantly, PCR analysis of colonies from the
integration of “empty vectors” (Figure S8) yielded single bands,
indicating the presence of only one platform cassette. If there
had been more than one platform cassette within the HAC,
after each integration event, we should obtain more than one
band in the PCR analysis, i.e., one band for the platform
cassette with the inset and one without. Thus, we can conclude
that our IIS-HAC-based integration system has only one copy
of inserted platform cassette.
Microcell-Mediated Chromosome Transfer (MMCT)
Technique. The alphoidtetO-HAC containing platform cassette
A037 was moved from chicken DT40 cells to hamster CHO
cells using an improved microcell-mediated chromosome
transfer technique.44 After MMCT transfer six clones were
obtained. PCR of genomic DNA isolated from these clones and
FISH analysis conﬁrmed the presence of an autonomous HAC
in ﬁve clones. Clone #CHO BH3:37 was selected for further
experiments.
Fluorescence In Situ Hybridization (FISH). FISH analysis
was performed as following. Hamster CHO cells carrying the
alphoidtetO-HAC bearing the platform cassette A037 were
cultured in F12 medium with 10 μg/mL of colcemid
(Invitrogen) overnight at 37 °C. Metaphase cells were
trypsinized and centrifugated for 4 min at 172g, treated in 10
mL of 50 mM KCl hypotonic solution for 20 min at 37 °C and
washed three times in methanol:acetic acid (3:1) solution with
a 4 min centrifugation at 172g between each wash. Cells were
diluted to the appropriate density with ﬁxative solution, spread
onto precleaned slides (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) above steam (boiling water), and allowed to age 2
days at room temperature. For BAC probing, CHO metaphase
slides were washed in 70% formamide in 2× SSC for 2 min at
72 °C. Samples were dehydrated through a 70, 90, and 100%
ethanol series for 4 min each and left to air-dry. The probe used
for FISH was BAC32−2-mer(tetO) DNA containing 40 kb of
alphoid-tetO array cloned into a BAC vector as described
previously.11 BAC DNA was labeled using a nick-translation kit
with Orange 552 dUTP (5-TAMRA-dUTP) (Abbott Molec-
ular). The probe was denatured in hybridization solution at 78
°C for 10 min and left at 37 °C for 30 min. The hybridization
mix probe was applied to the sample and incubated at 37 °C
overnight. Slides were washed with 0.4× SSC, 0.3% Tween 20
for 2 min at 72 °C, brieﬂy rinsed with 2× SSC, 0.1% Tween 20
(10 s) and air-dried in darkness. The samples were counter-
stained with VECTASHIELD mounting medium containing
DAPI (Vector Laboratories, Burlingame, CA, USA). Slides were
analyzed by ﬂuorescence microscopy. Images were captured
using a DeltaVision imaging system in the CRC, LRBGE
Fluorescence Imaging Facility (NIH) and analyzed using
ImageJ software (NIH).
Plasmid DNA Transfection and Loading into Al-
phoidtetO-HAC. CHO cells with the alphoidtetO-HAC were
cotransfected with Type I carrier plasmid A167 and A139
plasmid expressing ΦC31 integrase and Cre recombinase for
the ﬁrst and third rounds of insertion or with Type II carrier
plasmid A169 and A135-JH plasmid expressing ΦBT1 integrase
and Cre recombinase for the second round of insertion. Brieﬂy
1 × 105 CHO cells were seeded in one well of a 6-well plate in
growth media without selection antibiotics. Next day, 200 μL of
Opti-MEM (Gibco), 6 μL of X-tremeGENE 9 DNA Trans-
fection Reagent (Roche) 1.8 μg of A167 and 0.2 μg of A139 or
1.8 μg A169 and 0.2 μg A135-JH plasmids were mixed,
incubated 20 min at room temperature and added to the cells
dropwise. Next day, the cells were trypsinized and transferred
to two 100 mm culture dishes with growth media containing 5
μg/mL Blasticidin S and 5 μg/mL Puromycin in case of the
ﬁrst and third rounds of insertion or 5 μg/mL Blasticidin S and
200 μg/mL Hygromycin B in the case of the second round.
The cells were cultured for 7−10 days until colonies of about 1
× 103 cells formed. Individual colonies were transferred to a 24-
well plate and cultured in media with 5 μg/mL Blasticidin S, 5
μg/mL Puromycin and 10 μg/mL Ganciclovir or 5 μg/mL
Blasticidin S, 200 μg/mL Hygromycin B and 160 μg/mL 5-
Fluorocytidine.
PCR Reaction. Genomic DNA was extracted from CHO
cultured cells containing the alphoidtetO-HAC with DNeasy
Blood & Tissue Kit (Qiagen). DNA concentration was
measured by NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientiﬁc). The PCR mixture included 0.5 μL TaKaRa
LA Taq (5 units/μL, Clontech, #RR002M, Lot KA3101CA), 5
μL 10× LA PCR Buﬀer, 8 μL dNTP mixture (2.5 mM each),
300 ng of genomic DNA, 2 μL forward and 2 μL reverse
primers (10 μM), sterile distilled water up to 50 μL. PCR
products were resolved on 1% or 2% agarose gels.
Construction of VHL Gene Fragment-Containing
Plasmids and Loading into AlphoidtetO-HAC. Three
fragments containing either exon 1, exon 2 or exon 3 of the
VHL gene were PCR-ampliﬁed from the TAR-isolated YAC/
BAC clone containing a full-length genomic copy of the VHL
gene13 using speciﬁc primers (Table S1). The fragments were
cloned into the appropriate plasmids as follows: a 5990 bp
AscI-FseI fragment 1 containing exon 1 along with the VHL
promoter was inserted into Type 1 carrier vector A168 digested
by AscI/FseI restriction enzymes; a 4221 bp Asc1-Not1
fragment 2 containing exon 2 was inserted into Type 2 carrier
vector A170 digested by AscI/NotI restriction enzymes; a 6323
bp Asc1-NotI fragment 3 containing exon 3 was inserted into
Type 1 carrier vector A168 digested by AscI/NotI restriction
enzymes. Three rounds of insertion were performed to
assemble a full-length VHL gene on the HAC. For the ﬁrst
round of insertion, 3 μg of the exon 3-carrying vector and 2 μg
of ΦC31-Cre-expressing A139 vector were cotransfected into
CHO cells carrying the alphoidtetO-HAC bearing the previously
inserted platform cassette A037 using the appropriate trans-
fection reagents (MTI-GlobalStem). Four μg/mL Puromycin
ACS Synthetic Biology Research Article
DOI: 10.1021/acssynbio.7b00209
ACS Synth. Biol. XXXX, XXX, XXX−XXX
J
plus 4 μg/mL Blasticidin S were used as a positive selection for
5 days and 4 μg/mL Puromycin, 4 μg/mL Blasticidin S and 5
μg/mL Gancyclovir were used as a positive/negative selection
for 1 week to select for correct insertion of exon 3. For the
second round of insertion, 3 μg of exon 2-carrying vector and 2
μg of ΦBT1-Cre-expressing A135-JH vector were cotransfected
into CHO cells. 100 μg/mL Hygromycin B plus 4 μg/mL
Blasticidin S were used as a positive selection for 5 days. 100
μg/mL Hygromycin B, 4 μg/mL Blasticidin S and 100 μg/mL
5-Fluorocytidine were used as a positive/negative selection for
1 week to select for correct insertion of exon 2. For the third
round of insertion, 3 μg of the exon 1-carrying vector and 2 μg
of ΦC31-Cre-expressing A139 vector were cotransfected into
hamster CHO cells. Four μg/mL Puromycin plus 4 μg/mL
Blasticidin S were used as a positive selection for 5 days and 4
μg/mL Puromycin, 4 μg/mL Blasticidin S and 5 μg/mL
Gancyclovir were used as a positive/negative selection for 1
week to select for correct insertion of exon 1. All insertions
after each round were conﬁrmed by PCR with the
corresponding primers (Table S1) that diagnose a correctly
assembled VHL gene.
RT-PCR Reaction. Transcription of the VHL gene from
alphoidtetO-HAC/VHL in hamster CHO cells was detected by
RT-PCR by using speciﬁc primers described in Table S1.
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